A global opportunity of 300 billion euros
Currently, the medications available (like minoxidil and finasteride) have limited efficacy and are not fully available to women.
On the other hand, hair transplants are expensive, invasive, and painful. Many people won’t pursue this procedure due the scars and social stigma.
StimuSIL will be to hair transplants what Botox® was to facelift surgeries: A discreet, painless, non-invasive option that will dramatically expand the current market.
StimuSIL is sold as a single-use device + cartridge combination.
StimuSIL has proprietary technology and a scalable business model.
When using conventional lasers, most of the light is blocked and lost due to the melanin layer of the skin, resulting in minimal beneficial effects. StimuSIL’s precision system allows light to reach the hair follicle directly, maximizing the light’s benefit.
Clinic margins will be greater than 60% since lower-cost aesthetic assistants can also carry out the treatment.
Thanks to the economies of scale of consumables, StimuSIL’s net margin is 80%.
Market launch in 2025
- Pre-launch (2025): Using Key Opinion Leaders to build confidence in the product using success stories with Before and After photos.
- Official Launch (2026): Creating global PPRR campaigns and regional clinic activation
- Working with leading dermatologists, trichologists, and aesthetic doctors
- Collaboration with established distributors
- From 2027 onward: Focus on improving productivity in clinics and expanding the use of cartridges
In the clinical testing phase
Currently conducting a pilot study to test efficacy and safety with 38 patients.
Promising efficacy results in mice: reversing up to 55% of induced alopecia.
Tests in pigs have demonstrated the safety of the device.
Project led by
Chairman: Pablo Villalba (2 exits)
CEO: Ana Villalba (formerly Head of Growth at Lingokids)
CSO: Dr. Mehmet Kosoglu (10+ years of FDA experience with two patents to his name)
CMO: Dr. Scott Gerrish (KOL in aesthetics and owner of two clinics in the US)
